Ansell’s Key Takeaways on Advanced Hodgkin Lymphoma From SOHO 2024

Stephen M. Ansell, MD, PhD, chair of the Division of Hematology at Mayo Clinic in Rochester, Minnesota, discusses the key takeaways from his session at 2024 Society of Hematologic Oncology (SOHO) Annual Meeting in the advanced stage Hodgkin lymphoma space.

Here, Ansell highlights additional discussions from the meeting that are of particular interest to a community oncologist, including how to incorporate immunotherapies in the treatment of patients with lymphomas.

Transcription:

0:09 | The key takeaways are that this is a field that is moving fast. I think within the US, there is a greater kind of embracing of the nivolumab [Opdivo] and AVD [doxorubicin, vinblastine, and dacarbazine] chemotherapy regimen. I certainly would say that it has advantages, because one can use it in almost any population with good results. Comparisons of in the [younger] patients and comparisons in the [older] patients, compared with brentuximab and AVD shows benefit for the nivolumab and AVD. I think a takeaway for a community oncologist is that this is probably going to become the standard of care.

0:44 | Speaking of community oncologists, there [were] a number of discussions [at the SOHO 2024 Annual Meeting] about how to integrate immunotherapies, not so much now in Hodgkin lymphoma, but in other lymphomas like low-grade lymphomas and large cell lymphoma, particularly bringing bispecific antibodies to the community. Those are agents that are highly effective, but with some toxicity in the first month. How to use that in a community setting in a safe and effective way is one of the things being discussed. I certainly think it is one of those things that we will get it worked out, and it will be usable and useful across the board.

REFERENCE:

Ansell SM. Advanced Stage Hodgkin Lymphoma, the End of ABVD and BEACOPP? Presented at: 2024 SOHO Annual Meeting; September 4-7, 2024; Houston, Texas.